Competitive problems in the drug industry: hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninety-first Congress, first session ...
United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly and Anticompetitive Activities, United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly
U.S. Government Printing Office, 1975
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
acquisition cost action activities actual Administration agencies Association basis believe bioavailability Board brand central CHAIRMAN committee competitive considered continue cost Defense Department determine develop Director discuss dispensing drug product effective effort equivalent established fact Federal Food and Drug GORDON Government implementation increase indicated inspection involved issue Labs laws letter manufacturers Maximum Allowable meeting ment Office patient percent Pharmaceutical pharmacists pharmacy physician practice prescribed prescription present problems procedures procurement professional proposed purchasing quality assurance question reasonable RECALLER received recommendations regulations reimbursement representatives Research responsibility result savings Schedule Secretary selected Senator specific standards statement Subcommittee supply Tablets testing therapeutic tion United wholesale
Page 12087 - Since many agencies, including the Food and Drug Administration in the Department of Health, Education and Welfare, in which the appellant was employed, have nothing to do with national security, the Act of 1950 has nothing to do with them. The authorization to bring "other...
Page 11700 - I AM PLEASED TO BE HERE TODAY AND TO HAVE THE OPPORTUNITY TO ASK QUESTIONS OF SECRETARY JACKSON.
Page 12328 - Engineering before the Subcommittee on Health of the Senate Committee on Labor and Public Welfare, 94th Cong., 1st Sess.
Page 12055 - The hearing need not be conducted according to technical rules relating to evidence and witnesses. Any relevant evidence shall be admitted if it is the sort of evidence on which responsible persons are accustomed to rely in the conduct of serious affairs, regardless of the existence of any common law or statutory rule which might make improper the admission of such evidence over objection in civil actions.
Page 11663 - OF THE SELECT COMMITTEE ON SMALL BUSINESS, Washington, DC The subcommittee met, pursuant to notice, at 10 am, in room 2221.
Page 11925 - Action is pleased to have the opportunity to present its views on the $12.7 billion supplemental appropriation for America's efforts in Vietnam.
Page 11732 - STATEMENT OF ALEXANDER M. SCHMIDT, MD, COMMISSIONER, FOOD AND DRUG ADMINISTRATION; ACCOMPANIED BY J. RICHARD GROUT, MD, DIRECTOR, BUREAU OF DRUGS; PETER BARTON »HUTT, ASSISTANT GENERAL COUNSEL; LLOYD B. TEPPER, MD, ASSOCIATE COMMISSIONER FOR SCIENCE; BARRETT SCOVILLE, MD, ACTING DIRECTOR OF THE DIVISION OF BUREAU OF NEUROt PHARMACOLOGICAL PROJECTS; AND ROBERT WETHERELL, DIRECTOR, OFFICE OF LEGISLATIVE SERVICES Dr.
Page 12055 - substantial evidence" means : Evidence consisting of adequate and well controlled investigations, including clinical investigations by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling...